Similar articles

• Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?

  Shurin MR, Gregory M, Morris JC, Malyguine AM. Shurin MR, et al. Expert Opin Biol Ther. 2010 Nov;10(11):1539-53. doi: 10.1517/14712598.2010.526105. Expert Opin Biol Ther. 2010. PMID: 20955111 Review.
• Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.

  Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K. Bonehill A, et al. Cancer Res. 2003 Sep 1;63(17):5587-94. Cancer Res. 2003. PMID: 14500399
• RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.

  Hsu AK, Kerr BM, Jones KL, Lock RB, Hart DN, Rice AM. Hsu AK, et al. Biol Blood Marrow Transplant. 2006 Aug;12(8):855-67. doi: 10.1016/j.bbmt.2006.05.004. Biol Blood Marrow Transplant. 2006. PMID: 16864056 Clinical Trial.
• Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.

  Miura S, Kagamu H, Tanaka H, Yoshizawa H, Gejyo F. Miura S, et al. Scand J Immunol. 2008 Apr;67(4):385-91. doi: 10.1111/j.1365-3083.2008.02083.x. Epub 2008 Feb 14. Scand J Immunol. 2008. PMID: 18282232
• Cancer immunotherapy with mRNA-transfected dendritic cells.

  Gilboa E, Vieweg J. Gilboa E, et al. Immunol Rev. 2004 Jun;199:251-63. doi: 10.1111/j.0105-2896.2004.00139.x. Immunol Rev. 2004. PMID: 15233739 Review.